New Five-Year Data Support Superiority of Novartis Drug Tasigna® Over Gleevec

New five-year data support superiority of Novartis drug Tasigna® over Gleevec
"These new and updated data reaffirm the superiority of Tasigna over Gleevec at achieving deeper molecular responses and provide even more evidence supporting Tasigna as an appropriate treatment of choice in newly diagnosed patients and in those who …
Read more on MarketWatch


Novartis to highlight long-term data, innovative pipeline for patients with
"At this exciting time in cancer research, we are presenting new long-term findings on well-established, targeted therapies while also reporting early data on innovative treatment approaches and compounds in areas of high unmet patient need, including …
Read more on MarketWatch

Comments are closed.